Home › Trials › NCT07010198
Clinical trial Recruiting at 1 site Observational Ages 35 and up

Comparing different ways to screen for liver cancer in people with hepatitis B in Zhongshan City

Official title: Head-to-Head Comparison of Hepatocellular Cancer (HCC) Screening Strategies: A Prospective Population-Based Cohort Study in Zhongshan City

Run by Zhongshan People's Hospital, Guangdong, China · NCT07010198 · Data updated 2026-11-12

This project tests different screening methods to see which finds liver cancer earliest in adults 35 and older who are positive for hepatitis B in Zhongshan City.

More Hepatocellular Carcinoma (HCC) trials

Quick facts

Study typeObservational
Ages35 Years and up
SexAll
Enrollment4500 (estimated)
SponsorZhongshan People's Hospital, Guangdong, China
Academic / other
Locations1 site (Zhongshan, Guangdong)
StatusRecruiting
StartedMarch 1, 2025
Main results expectedDecember 31, 2025
Study endsDecember 31, 2028
Registry record updatedJune 8, 2025
Trial IDNCT07010198 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 35 or older who live in Zhongshan, test positive for HBsAg, can provide informed consent, and do not have a prior history of liver cancer or liver transplantation.

Probably not a fit

People who are HBsAg-negative, younger than 35, pregnant, have prior liver cancer or transplant, have severe comorbidities, or cannot consent are unlikely to receive benefit from participating.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, single-center, population-based head-to-head comparison of multiple hepatocellular carcinoma (HCC) screening strategies in Zhongshan City. The study will recruit roughly 4,500 HBsAg-positive adults through an initial HBV screening phase and then follow them with uniform HCC surveillance using AFP plus liver ultrasound every six months. Different risk stratification models (conventional AFP+ultrasound general strategy, REACH-B, AGED, aMAP, and aMAP 3.0) will be applied concurrently to each participant to compare detection rates and risk classification. Clinical and laboratory measures such as quantitative HBeAg and other indicators required for the risk scores will be collected and monitored during follow-up.

Why it matters

Potential benefit: If successful, this could identify the most effective screening approach to detect liver cancer earlier in people with chronic hepatitis B, improving chances for curative treatment.

How similar studies have gone: Retrospective validation in Xiaolan Town showed promising results for the five scoring methods, but a prospective head-to-head comparison in this population is novel.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Voluntarily sign the informed consent form.
* Household registration in Zhongshan City, Guangdong Province.
* Aged 35 and above.
* Positive screening result for Hepatitis B surface antigen (HBsAg).

Exclusion Criteria:

* Previous history of liver cancer or liver transplantation.
* Pregnant women.
* Severe comorbidities (e.g., end-stage cardiopulmonary diseases, advanced malignancies).
* Individuals lacking legal capacity or unable to provide informed consent.

Where it's running

  • Zhongshan People's Hospital
    Zhongshan, Guangdong, China     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Hepatocellular Cancer (HCC) 2Zhongshan People's Hospital, Guangdong, China 6
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.